CD70: An emerging target in cancer immunotherapy.

J Jacobs, V Deschoolmeester, K Zwaenepoel, C Rolfo, K Silence, S Rottey, F Lardon, E Smits, P Pauwels

Pharmacology & therapeutics 2015 Nov

filter terms:

Over the last decades, advances in the knowledge of immunology have led to the identification of immune checkpoints, reinvigorating cancer immunotherapy. Although normally restricted to activated T and B cells, constitutive expression of CD70 in tumor cells has been described. Moreover, CD70 is implicated in tumor cell and regulatory T cell survival through interaction with its ligand, CD27. In this review, we summarize the targetable expression patterns of CD70 in a wide range of malignancies and the promising mechanism of anti-CD70 therapy in stimulating the anti-tumor immune response. In addition, we will discuss clinical data and future combination strategies. Copyright © 2015 Elsevier Inc. All rights reserved.

Citation

J Jacobs, V Deschoolmeester, K Zwaenepoel, C Rolfo, K Silence, S Rottey, F Lardon, E Smits, P Pauwels. CD70: An emerging target in cancer immunotherapy. Pharmacology & therapeutics. 2015 Nov;155:1-10